Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

ation (FDA) in October 2008 for PHN, which was accepted and filed by the FDA in December 2008. On March 19, 2009, a marketing authorization application (MAA) for Qutenza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. The Company is currently awaiting the European Commission's decision on the CHMP's opinion, a process which normally takes approximately 60 to 90 days.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing and outcome of regulatory decisions and the label approval being sought or that may be obtained with respect to the MAA for Qutenza in the European Union and the NDA for Qutenza with the FDA, including the timing of European Commission decision on the MAA and the PDUFA date for
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna ... McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ ... of an otherwise non-healing surgical knee wound. , The case involved a 78-year-old ...
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... United Kingdom -based Lab M Holdings, a developer, ... systems. Lab M was founded in ... microbial testing and diagnostic products for the global food, ... sells into more than 70 countries worldwide, and has ...
(Date:8/27/2015)... , Aug. 27, 2015 The ... a patient,s eyes—and life—were saved by doctors at Vanderbilt ... working with NNFF, NovaBay Pharmaceuticals and Dr. John ... Center at Seton Medical Center in ... treatment used a breakthrough approach, pioneered by Dr. Crew, ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... , COLUMBIA, S.C. , Jan. 19 ... the University of South Carolina,s Jones Physical Science ... scientific experiments. , The 33,000-square-foot project included the renovation of ... Cancer Research, which was established in 2002 by the Center ...
... , LEXINGTON, Ky. , Jan. 19 ... that it will be changing its name to VHGI Holdings, ... healthcare. According to Jim Renfro , VHGI President, "This ... to demonstrate our company,s commitment on asset diversification and creating ...
... , , , BANGALORE, India ... by Their Side, This Case Challenged Medical Excellence , ... Wockhardt Hospitals, Bangalore (Now a Network Hospital of Fortis),has performed a ... Brendan was suffering from congenital heart defect called - Tetralogy of,Fallot or ...
Cached Biology Technology:Hendrick Construction Renovates USC Science Building 2VirtualHealth Technologies Will Change Its Name to VHGI Holdings, Inc. and Surges Forward Into Broader Market 2VirtualHealth Technologies Will Change Its Name to VHGI Holdings, Inc. and Surges Forward Into Broader Market 32-Year-old Baby With Complex Heart Deformity Undergoes Major Open Heart Surgery at Wockhardt Hospitals, Bangalore - (now a Network Hospital of Fortis) Without any Blood Transfusion 22-Year-old Baby With Complex Heart Deformity Undergoes Major Open Heart Surgery at Wockhardt Hospitals, Bangalore - (now a Network Hospital of Fortis) Without any Blood Transfusion 3
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... bacteria which prevent the body from successfully fighting off the ... in new research published today. , The study found ... work together to hamper the body's efforts to fight off ... bacteria's DNA by the body's white blood cells, which are ...
... new survey by researchers at Oregon State University and ... rivers and streams in the western United States found ... the more than 2,700 fish analyzed in the study ... the element throughout 12 western states caught the researchers ...
... University of Illinois at Champaign-Urbana have found that people ... in western Uganda are exchanging gastrointestinal bacteria ?specifically Escherichia ... E. coli strains migrating to chimps are resistant to ... study will appear in the April 2007 issue of ...
Cached Biology News:Scientists identify specific enzymes that make meningitis hard to fight 2Study finds mercury prevalent in many western fish 2Study finds mercury prevalent in many western fish 3E. coli bacteria migrating between humans, chimps in Ugandan park 2E. coli bacteria migrating between humans, chimps in Ugandan park 3
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Biology Products: